Vaxart, Inc.’s Oral H1N1 Influenza Vaccine Generates Protective Immunity
1/9/2014 10:20:57 AM
SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than by injection, today announced positive safety and immunogenicity data from a phase Ib clinical dose-ranging study with its oral H1N1 seasonal influenza vaccine candidate. This study follows a phase I study, the positive results of which were announced in June 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by